579 related articles for article (PubMed ID: 31852816)
1. Vascular safety of erenumab for migraine prevention.
Kudrow D; Pascual J; Winner PK; Dodick DW; Tepper SJ; Reuter U; Hong F; Klatt J; Zhang F; Cheng S; Picard H; Eisele O; Wang J; Latham JN; Mikol DD
Neurology; 2020 Feb; 94(5):e497-e510. PubMed ID: 31852816
[TBL] [Abstract][Full Text] [Related]
2. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
Ashina M; Kudrow D; Reuter U; Dolezil D; Silberstein S; Tepper SJ; Xue F; Picard H; Zhang F; Wang A; Zhou Y; Hong F; Klatt J; Mikol DD
Cephalalgia; 2019 Dec; 39(14):1798-1808. PubMed ID: 31707815
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
Lampl C; Kraus V; Lehner K; Loop B; Chehrenama M; Maczynska Z; Ritter S; Klatt J; Snellman J
J Headache Pain; 2022 Aug; 23(1):104. PubMed ID: 35978286
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G
JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
Zhou Y; Zhang F; Starcevic Manning M; Hu Z; Hsu CP; Chen PW; Peng C; Loop B; Mytych DT; Paiva da Silva Lima G
Cephalalgia; 2022 Jul; 42(8):749-760. PubMed ID: 35272533
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
10. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
12. A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
[TBL] [Abstract][Full Text] [Related]
13. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
14. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
[TBL] [Abstract][Full Text] [Related]
15. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
18. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
19. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
Garland SG; Smith SM; Gums JG
Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
[No Abstract] [Full Text] [Related]
20. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
